NEW YORK (GenomeWeb News) – Investment Bank Leerink Swann this week upgraded its rating on Bio-Rad Laboratories' stock from "market perform" to "outperform," citing a favorable trend for the firm's diagnostics business over the immediate term. The bank also placed a 12-month valuation range of between $107 and $114 on the stock. Bio-Rad closed Wednesday, the day the note was issued, at $98.75.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.